Shionogi agreed to acquire Austin-based IntraBio for $2 billion upfront, buying all outstanding shares. The deal would make IntraBio a wholly owned subsidiary of Shionogi’s U.S. arm.
The centerpiece is AQNEURSA (levacetylleucine), for which Shionogi would gain global intellectual-property and commercialization rights. It is approved for neurological symptoms of Niemann-Pick disease type C and, more recently, ataxia associated with ataxia-telangiectasia.
Shionogi says IntraBio’s rare-disease expertise and pipeline—including programs in Pompe disease, Fragile X syndrome, and Jordan’s syndrome—will strengthen its expansion into rare neurological conditions.
The agreement is subject to customary closing conditions and regulatory clearances. Shionogi expects completion between November and December 2026.
The acquisition continues Shionogi’s push to grow beyond its traditional infectious-disease focus and build out a rare-disease business.
Sources:
Shionogi Continues Rare Disease Expansion With ...
www.shionogi.com · us · enShionogi Continues Rare Disease Expansion With Planned ...
Shionogi pays $2B to acquire a rare disease startup
Transaction will add AQNEURSA® (levacet
Shionogi acquires rare disease startup IntraBio for $2 billion
Shionogi acquires IntraBio to bolster rare disease business
米国IntraBio社の完全子会社化に関するお知らせ｜ 塩野義製薬
Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition - MedCity News
Shionogi pays USD 2bn for IntraBio and two-indication rare ...
Shionogi to Acquire IntraBio for $2 Billion
Shionogi to acquire IntraBio for $2 billion in rare disease ...
Shionogi's diversification continues with $2bn IntraBio buy
Kirkland Advises IntraBio on Sale to Shionogi | News
Shionogi to Acquire US Rare Disease Biotech for $2 Billion (1)